Louie Pasculli

Real-world data from Teva Pharmaceuticals’ IMPACT-TD Registry showed that deutetrabenazine and its extended-release formulation led to significant reductions of involuntary movements and improved quality of life for adults with tardive dyskinesia.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is neural network plasticity after stroke!

A recent study confirms satralizumab's long-term safety and efficacy for treating neuromyelitis optica spectrum disorder, supporting its use as a maintenance therapy.

Acumen Pharmaceuticals initiates a phase 2 trial extension for sabirnetug, targeting early Alzheimer disease and aiming for long-term safety insights.

The medical director of the stroke recovery program at Hackensack Meridian Health JFK Johnson Rehabilitation Institute provided clinical insights into her presentation focused on expanding rehab care for stroke survivors across settings. [WATCH TIME: 5 minutes]

Carrie Haverty, MS, CGC, NSGC president-elect, discusses the evolving role of genetic counselors, emphasizing personalized care, gene therapy advancements, and the need for multidisciplinary integration in health care.

At MDS 2025, the lead specialist for patient insights at Lundbeck spoke about the importance of considering patient and caregiver voices when designing clinical trials. [WATCH TIME: 3 minutes]

A new study confirms the Nerivio REN wearable provides long-term, drug-free migraine relief without dosage increases, ensuring consistent effectiveness over 3 years.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on CAR-T therapy for autoimmune neurologic diseases!

Cladribine shows superior efficacy over S1P modulators in reducing disability progression in treatment-naive relapsing-remitting MS patients.

Beatrice Yang, MSc, lead specialist for patient insights at Lundbeck, discussed how incorporating patient and caregiver feedback helped shape the design of a phase 3 multiple system atrophy trial to make participation more practical and patient-centered.

The president of the National Society of Genetic Counselors discussed the 2025 NSGC conference, highlighting AI and gene therapies as key topics, while noting the importance of genetic counselors in clinical care. [WATCH TIME: 4 minutes]

Jupiter Neurosciences advances Parkinson treatment with FDA clearance for JOTROL's phase 2a trial, showcasing promising safety and bioavailability results.

Caregivers share insights on discussing social determinants of health in pediatric clinics, revealing preferences for surveys over in-person conversations.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on the 2025 AANEM Annual Meeting!

A new study presented at the National Society of Genetic Counselors Annual Conference highlights strong interest among individuals at risk for Huntington disease in undergoing modifier gene testing, underscoring the growing role of genetic insights in personal and clinical decision-making.

A new study reveals that early treatment with the Nerivio wearable significantly enhances migraine relief, doubling efficacy outcomes for patients.

A 2025 study published in Neurology® found that people with both gum disease and dental cavities face significantly higher long-term risks of stroke and major cardiovascular events compared with those with good oral health.

An investigator at Kuakini Health Systems spoke about the global importance of the Honolulu-Asia Aging Study, highlighting its history and findings, including data surrounding the diagnosis of neurodegenerative diseases. [WATCH TIME: 11 minutes]

A physician assistant who specializes in neurology previewed her upcoming presentation on evaluating patients with headache at the 2025 Baptist Miami Neuroscience Symposium.

A phase 3 study evaluates remibrutinib's safety and efficacy for generalized myasthenia gravis, promising new treatment options for patients.

A phase 3 study will evaluate iptacopan's efficacy in treating generalized myasthenia gravis, focusing on daily living activities and safety outcomes.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on the 2025 AANEM Annual Meeting!

A perspective model aimed noted that introducing efgartigimod alfa for patients with chronic inflammatory demyelinating polyneuropathy incurs more expected costs.

An open-label extension trial testing the efficacy of nipocalimab in patients transitioning from placebo revealed continued improvement in MG-Activities of Daily Living scores over a long-term period.

A post-hoc analysis study revealed apomorphine sublingual film was efficacious over a long term period across various age ranges, including elders, with Parkinson disease.

Mark Forman, MD, PhD, chief medical officer at Ventyx Biosciences, discussed promising early-stage data of VTX3232, an NLRP3 inflammasome in development for early-stage Parkinson disease.

A recent meta-analysis reveals frontotemporal dementia's incidence and prevalence, highlighting its significance in clinical research and treatment advancements.

The FDA has granted fast track designation to Eisai’s etalanetug, an anti-tau antibody targeting tau pathology in Alzheimer's disease.

Clinical trial data presented at the 2025 International Congress of Parkinson’s Disease and Movement Disorders showed that pimavanserin had positive efficacy in patients showing Parkinson Disease psychosis symptoms who were treated earlier.